Core Viewpoint - The article discusses the death of musician Gou Wei, highlighting the health risks associated with sleep apnea, particularly its link to nasal polyps and the lack of diagnosis in China [2][3]. Group 1: Health Risks and Statistics - Gou Wei suffered from nasal polyps and was preparing for surgery before his death due to sleep apnea [2]. - Sleep apnea is a common chronic condition that can be fatal, with an estimated 176 million people in China aged 30 to 69 potentially affected, yet the diagnosis rate is below 1% [2]. - If sleep apnea is not effectively managed, it can lead to severe consequences, including hypertension, which affects over 47% of sleep apnea patients in China [3]. Group 2: Treatment Developments - GLP-1 weight loss drugs have shown efficacy in treating obstructive sleep apnea, with the FDA approving Liraglutide for this purpose in December [3]. - This treatment is the first globally to address both obesity and moderate to severe sleep apnea, with applications submitted in China for regulatory approval [3].